Rapamycin (Sirolimus) Research Overview (also known as Sirolimus, Rapamycin, AY-22,989, Rapamune)
Rapamycin, also called sirolimus, is a macrolide compound that forms a complex with FKBP12 and inhibits mechanistic target of rapamycin complex 1 (mTORC1), a central regulator of growth, nutrient sensing, autophagy, and immune-cell activity. It is primarily studied in longevity biology, geroscience, transplantation, immunology, cancer biology, and metabolic research, while its human anti-aging use remains investigational.
What Is Rapamycin (Sirolimus)?
Rapamycin is a naturally derived macrolide originally isolated from soil collected on Easter Island, or Rapa Nui. It was initially characterized for antifungal activity, but subsequent research established that its most important biological effects involve inhibition of the mammalian or mechanistic target of rapamycin pathway. Sirolimus is the approved pharmaceutical name for rapamycin and is used clinically as an immunosuppressant in selected transplantation settings and in certain vascular and oncologic applications. The compound is available in oral formulations, and its pharmacology is influenced by absorption, hepatic metabolism, drug interactions, and substantial interindividual variation in blood concentrations.
In longevity research, rapamycin is studied because mTOR signaling integrates amino acids, insulin, growth factors, cellular energy, and stress signals. Persistent nutrient and growth signaling can promote protein synthesis and cellular growth while suppressing autophagy, whereas partial or intermittent pathway inhibition may activate cellular maintenance programs. Lifespan extension has been demonstrated in several laboratory organisms, most prominently in genetically heterogeneous mice. However, evidence that rapamycin extends healthy lifespan in otherwise healthy humans is not yet conclusive, and anti-aging use should be regarded as experimental rather than established medical care.
Research Indications
mTOR Pathway Modulation
mTORC1 inhibition
Sirolimus binds FKBP12 to form a complex that selectively inhibits mTOR complex 1, reducing nutrient-responsive anabolic signaling and protein synthesis.
Autophagy-related signaling
mTORC1 suppression is a well-established upstream signal for autophagy initiation in cell and animal research models.
Longevity Research
Lifespan extension in model organisms
Rapamycin extends lifespan in yeast, flies, worms, and genetically heterogeneous mice; these findings do not establish a human longevity indication.
Late-life intervention studies
Mouse studies report lifespan benefits even when treatment begins in midlife or later, supporting continued investigation of timing and dosing schedules.
Immune Aging Studies
Responses to influenza vaccination
Low-dose mTOR inhibition has been studied in older adults for effects on immune function and influenza vaccine response, with regimen-dependent findings.
Infection-risk tradeoff
At conventional immunosuppressive exposure, sirolimus can increase susceptibility to infection; low-dose geroscience findings cannot be generalized to all populations.
Age-Related Healthspan
Metabolic and tissue outcomes
Preclinical studies examine effects on age-associated functional decline, but human healthspan outcomes remain unproven.
Intermittent dosing hypotheses
Intermittent schedules are being explored to balance mTORC1 modulation with adverse-effect burden; optimal human schedules are unknown.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Healthy-aging research | 0.5–1 mg | Once weekly | Oral |
| Intermittent research protocols | 2–6 mg | Once weekly or every 2 weeks | Oral |
| Immune-aging trial designs | 0.5–1 mg | Daily for defined cycles | Oral |
| Transplant immunosuppression | Therapeutic drug monitoring required | Specialist-directed | Oral |
Timing
Sirolimus has a long elimination half-life, so effects and adverse events may persist beyond the dosing day. Research schedules vary substantially; clinician-supervised laboratory monitoring is particularly important when use is ongoing or combined with CYP3A4-modifying medicines.
Peptide Interactions
Both influence nutrient-sensing pathways and glucose handling. Combined use may increase the need for monitoring of glycemic and gastrointestinal effects.
A strong CYP3A4 and P-glycoprotein inhibitor that can substantially raise sirolimus exposure; avoid unless a prescribing specialist directs management.
Potent CYP3A4 inhibition can markedly increase sirolimus concentrations and toxicity risk.
Grapefruit inhibits intestinal CYP3A4 and can increase oral sirolimus bioavailability. Product labeling advises avoidance.
CYP3A4 and P-glycoprotein induction may lower sirolimus exposure and make effects unpredictable.
Everolimus is a related mTOR inhibitor. Concurrent use may duplicate pharmacologic effects and adverse-event risks.
Reported Research Timeline
01Hours to days (reported in cited studies): oral absorption occurs after dosing, while mTOR pathway inhibition begins; no subjective benefit should be assumed.
02Days 1–7 (reported in cited studies): mouth irritation, rash, gastrointestinal symptoms, fatigue, or headache may occur; absence of symptoms does not confirm safety.
03Weeks 2–4 (reported in cited studies): with repeated exposure, changes in lipids, glucose regulation, blood counts, or liver-related laboratory values may become detectable.
04Weeks 4–12 (reported in cited studies): protocol studies may assess tolerability and laboratory trends; any immune, metabolic, or functional outcome requires controlled interpretation.
05Months 3–6 (reported in cited studies): cumulative tolerability and metabolic effects are more informative than acute impressions; clinician-directed monitoring remains important.
06Long term (reported in cited studies): human lifespan or healthspan benefit has not been established. Reassessment of risks, interactions, and ongoing rationale is essential.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Sirolimus is a prescription immunosuppressant; non-transplant use should be discussed with a clinician experienced in its risks and interactions.
Potential adverse effects include stomatitis, rash, edema, acne, diarrhea, elevated lipids, hyperglycemia, and cytopenias.
Avoid grapefruit and review all medicines, supplements, and antimicrobials for CYP3A4 or P-glycoprotein interactions.
Vaccination planning requires medical guidance; live vaccines are generally avoided during clinically immunosuppressive therapy.
Use is generally avoided in pregnancy and breastfeeding unless a specialist determines that benefits outweigh risks.
Seek Medical Attention If:
Fever, chills, persistent cough, painful urination, or other signs of a significant infection develop.
You develop shortness of breath, chest pain, coughing blood, or unexplained severe fatigue.
Severe mouth ulcers, widespread rash, facial swelling, blistering, or signs of an allergic reaction occur.
Unusual bruising, bleeding, black stools, severe abdominal pain, or jaundice develops.
Quality Indicators
Verified Marker
Licensed pharmacy dispensing
Prefer prescription product dispensed by a licensed pharmacy with traceable manufacturer, lot number, expiration date, and intact packaging.
Verified Marker
Strength and dosage-form labeling
The label should clearly state sirolimus strength in milligrams, tablet or oral-solution form, lot identifier, storage instructions, and expiry date.
Verified Marker
Manufacturer quality documentation
For compounded preparations, request a certificate of analysis covering identity, potency, microbial limits, and heavy-metal testing where applicable.
Acceptable Range
Independent analytical testing
If third-party testing is presented, it should be lot-specific and use an appropriate method such as HPLC for identity and potency rather than a generic certificate.
Quality Concern
Unverified research or supplement sources
Avoid products without pharmacy provenance, reliable lot traceability, stated milligram accuracy, or authentic batch-specific testing documentation.
Research Citations
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., et al., 2009, Nature - Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients
Kaeberlein, M., Powers, R. W., Steffen, K. K., et al., 2005, Science - Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster
Bjedov, I., Toivonen, J. M., Kerr, F., et al., 2010, Cell Metabolism - mTOR inhibition improves immune function in the elderly
Mannick, J. B., Del Giudice, G., Lattanzi, M., et al., 2014, Science Translational Medicine - The mechanistic target of rapamycin: The grand conducTOR of metabolism and aging
Kennedy, B. K., Lamming, D. W., 2016, Cell Metabolism
Research Focus
longevity, anti-aging, mTOR inhibition, mTORC1, autophagy, geroscience, immunology, transplantation, metabolic signaling
Frequently Asked Questions
What should researchers watch for with Rapamycin (Sirolimus)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Rapamycin (Sirolimus)?
Hours to days (reported in cited studies): oral absorption occurs after dosing, while mTOR pathway inhibition begins; no subjective benefit should be assumed.
How is Rapamycin (Sirolimus) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →